Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Nature Reviews Bioengineering (2023)
7 Altmetric
Metrics details
Cancer nanotherapy suffers from low-yield delivery that is imposed by tumour pathophysiological barriers. Top-down drug delivery strategies, including exosomes and cell membrane-coated particles, can improve safety and efficacy owing to the innate biointerfacial properties of these platforms. Here, we discuss the technological challenges that need to be overcome for their clinical implementation.
Nanodelivery enables the modulation of drug biodistribution and improves target site accumulation, thereby reducing toxicity and off-target effects1. However, a striking imbalance exists between the number of preclinical studies that use synthetic complex nanosystems and their poor clinical trial performance. One reason for such discrepancy is the formation of a protein corona, which masks surface ligands and triggers immunological responses. This protein coating is difficult to detect as its components vary between different animal models. Furthermore, the functionalizing ligands in synthetic nanosystems have heterogeneous orientation, pattern of distribution and concentration, thereby reducing targeting efficiency. Even polyethylene glycol (PEG) biointerfacing, which improves circulation half-life by reducing renal- and macrophage-mediated hepatic clearance, and has proved its efficacy in the mRNA vaccines against SARS-CoV-2, can lead to immunogenic events at higher doses and accelerate clearance and off-target release2. Nevertheless, simple systems (for example Doxil, Abraxane and Myocet) remain the gold-standard in oncology.
Current bottom-up conjugation and delivery strategies against cancer suffer from low specificity and efficacy owing to tumour heterogeneity and its associated pathophysiological barriers. Top-down systems, including biological exosomes and natural membrane-coated nanosystems, can help overcome these issues by preserving and expressing structural and functional self-recognition markers.
Having a specific size, shape, charge or functional moiety alone is no longer sufficient to ensure efficient cargo delivery to tumours. Unlike synthetic techniques, membrane-camouflaged abiotic nanosytems and exosomes benefit from the innate biointerfacial properties of natural membranes, including fluidity and antigenic profile. These top-down strategies have improved delivery efficiency owing to lower nonspecific uptake and improved homotypic targeting, which increase circulation half-life and promote immune modulation. Cell membrane-coated nanosystems first employed red blood cell (RBC) membranes, but they rapidly expanded to platelets, leukocytes, stem cells, cancer cells and bacteria. Exosomes have complex biomolecule-decorated bilayers that are enriched with tetraspanins, adhesion, cell-targeting and immune-escaping molecules, and a smaller size (typically 30–130 nm) than membrane-coated systems. Exosome-based systems differ from cell membrane-coated nanosystems in their manufacturing process, which can be either by isolation of natural exosomes or disintegration of large structures into smaller units. Furthermore, the methods of cargo loading in exosomes can be either exogenous, such as membrane-coating, or endogenous, which uses genetic and metabolic manipulation (Fig. 1a). The latter prevents the protein and nucleic-acid-based payload degradation that is normally observed in exogenously fabricated systems3.
a, Main characteristics of natural exosomes and cell membrane-coated nanosystems. b, Comparative analysis of end-product and manufacturing properties of natural exosomes and cell membrane-coated nanosystems. aa, amino acids.
The choice of a proper parent cell is crucial to ensuring targeting efficiency, because exosomal and membrane-coated systems retain most of the original membrane properties. For example, tumour cell membrane-coated nanosystems with surface markers, such as E-cadherin, CD44 and CD326, display homotypic targeting, and inhibit primary and metastatic tumour growth of breast cancer in rodents4,5. Similarly, intratumoural administration of platelet-coated polylactic acid nanoparticles carrying the toll-like receptor 7 (TLR7) agonist resiquimod results in tumour regression and protection against tumour challenges in a murine model of colorectal and breast cancer6.
Exosome-coated systems also possess homotypic targeting. Preclinical results have shown promising results with improved tumoural delivery in primary and metastatic targeted chemo-, gene- and immunotherapy. For example, intrapleural delivery of a single dose of autologous exosomes loading methotrexate resulted in tumour and CD163+ macrophage reduction in lung and colon rodent models with malignant pleural effusion3. Human and non-human derived drug-loaded exosome-based nanosystems are undergoing clinical trials (NCT01159288, NCT01294072, NCT02507583, NCT01550523, NCT01294072, NCT03608631 and NCT02657460).
Pharmacokinetic (PK) and pharmacodynamic (PD) properties of exosomes and cell membranes depend on the cell of origin and administration route. RBC and platelet coatings that express ‘don’t-eat-me’ signals outperform PEGylated nanomedicines in extending circulation half-life, passive tumour accumulation and safety5. Both cells can be conveniently collected autologously or from accessible blood banks. However, current studies on tumour cell membrane coating employ membranes from murine sources, and their clinical efficacy and safety in humans remain to be verified.
The half-life of exosome-based nanosystems is in the minute scale when injected systemically, and direct PK comparison with synthetic nanosystems is scarcely reported. For example, genetically enriched siRNA-packed exosomal nanosystems result in a 10-fold reduction of siRNA therapeutic dose compared with synthetic lipid systems7. However, how the immune system, parent cell and biomolecular composition affect PK and PD remain to be addressed.
Similar exogenous manufacturing processes exist for cell membrane- and exosome-coated nanosystems, including membrane extraction, synthetic core production and coating (fusion process). Nucleus-free cells are substantially easier to isolate and purify, which favours RBC and platelet usage. Extrusion and sonication are common coating methods in laboratory settings with moderate scalability8. The former method suffers from high material loss, whereas sonication leads to polydisperse coating, which can translate into unpredictable PK and PD. Tandem microfluidic–electroporation is a versatile alternative that grants homogeneous and biocompatible coatings9.
Delivery of hydrophilic payloads is more challenging for exosome-based systems compared with membrane-coated particles as the cargo does not diffuse through the vesicle membrane during exogenous incubation. Endogenous genetical and metabolic manipulation can address this issue, but it suffers from low production yield and heterogeneous loading efficiencies. This process is less aggressive than exogenous approaches, which improves safety and biodistribution by ensuring high targeting and cell-specific uptake3. However, it suffers from low yields and poor scalability. Furthermore, disintegration of parent cells into smaller units by extrusion or microfluidics improves production yield, compared to natural exosomes, but suffers from low homogeneity and biomimetic profile10.
Despite risking protein disruption, post-isolation chemical functionalization can unspecifically introduce ligands onto membrane proteins. Lipid tethering is less disturbing, but it still suffers from low coating homogeneity. Alternatively, hybrid cell coatings that combine several parent membranes blend the specific functionality of every parent cell, but substantial batch-to-batch heterogeneity and difficult optimization of the membranes’ ratio remain to be addressed.
The most valuable aspect of biomembrane-coating technologies in nanotherapeutics is to hijack otherwise inaccessible complex biological functionality. Both natural exosomes and membrane-coated nanosystems can be tailored towards high biocompatibility, low immunogenicity, protection of labile cargo and homotypic targeting. Careful selection of the cell of origin, fabrication process and post-isolation modifications could generate therapeutically superior cancer-tailored medicines (Fig. 1b).
For exosome production, moving to large bioreactors is essential to bypass low isolation yields. To tackle product heterogeneity, chemically defined media need to be implemented. For example, using human fluids and tissues as media could prove beneficial if the overall yield surpasses the problematic purification steps. Moreover, using immortalized cell lines can be considered, but monitoring the encapsulation of exogenous toxic reactants is necessary.
Effective cell membrane manufacturing depends not only on membrane isolation yields, but also on coating efficiency and homogeneity. Aggressive manipulation of the membranes can modify the surface and induce immunogenic responses after adminstration. Large-scale tandem microfluidic-electroporation approaches are a promising alternative to improve yield and end-product homogeneity.
From a regulatory perspective, characterization and quality control requirements are more stringent, including monitoring particle physicochemical properties, storage stability, batch-to-batch variation and surface molecule quantification. Despite the technological challenges that are associated with particle coating reproducibility, early phase clinical trials that use fruit-derived (NCT01294072) and patient-derived (NCT02657460) exosomes coatings have proved to be safe.
Combining natural and engineered structures could provide a more efficient and specific treatment against cancer. However, integrated effort from consortia of academics, clinicians, pharmaceuticals, engineers and regulatory authorities is essential to ensure their manufacture scalability and clinical impact.
Mendes, B. B. et al. Nanodelivery of nucleic acids. Nat. Rev. Methods Primers 2, 24 (2022).
Article  Google Scholar 
Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17, 20–37 (2017).
Article  Google Scholar 
Elsharkasy, O. M. et al. Extracellular vesicles as drug delivery systems: why and how? Adv. Drug Deliv. Rev. 159, 332–343 (2020).
Article  Google Scholar 
Qu, Y. et al. Cancer-cell-biomimetic nanoparticles for targeted therapy of multiple myeloma based on bone marrow homing. Adv. Mater. (2021).
Article  Google Scholar 
Fang, R. H., Kroll, A. V., Gao, W. & Zhang, L. Cell membrane coating nanotechnology. Adv. Mater. 30, 1706759 (2018).
Article  Google Scholar 
Bahmani, B. et al. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. Nat. Commun. 12, 1999 (2021).
Article  Google Scholar 
Reshke, R. et al. Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone. Nat. Biomed. Eng. 4, 52–68 (2020).
Article  Google Scholar 
Lopes, J. et al. Macrophage cell membrane-cloaked nanoplatforms for biomedical applications. Small Methods 6, 2200289 (2022).
Article  Google Scholar 
Rao, L. et al. Microfluidic electroporation-facilitated synthesis of erythrocyte membrane-coated magnetic nanoparticles for enhanced imaging-guided cancer therapy. ACS Nano 11, 3496–3505 (2017).
Article  Google Scholar 
Gimona, M., Pachler, K., Laner-Plamberger, S., Schallmoser, K. & Rohde, E. Manufacturing of human extracellular vesicle-based therapeutics for clinical use. Int. J. Mol. Sci. 18, 1190 (2017).
Article  Google Scholar 
Download references
J.M.J.M.R., J.C. and A.C.P.S. acknowledge the financial support from the Fundacão para a Ciência e a Tecnologia I.P. (FCT)-Research and Development Project grant PTDC/BTM-MAT/4738/2020. J.C. acknowledges financial support from the European Research Council-ERC Starting Grant 848325. The authors thank C. Alvarez-Lorenzo and P. Makvandi for their input and critical revision of this article.
ToxOmics, NOVA Medical School | Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, Lisboa, Portugal
João M. J. M. Ravasco & João Conde
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal
João M. J. M. Ravasco
Laboratory of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal
Ana Cláudia Paiva-Santos
LAQV/REQUIMTE, Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal
Ana Cláudia Paiva-Santos
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
J.M.J.M.R., J.C. and A.C.P.S. contributed to the conceptualization, writing, figure drawing and editing of the current manuscript.
Correspondence to Ana Cláudia Paiva-Santos or João Conde.
J.C. is a co-founder and shareholder of TargTex S.A. The remaining authors declare no competing interests.
Reprints and Permissions
Ravasco, J.M.J.M., Paiva-Santos, A.C. & Conde, J. Technological challenges of biomembrane-coated top-down cancer nanotherapy. Nat Rev Bioeng (2023).
Download citation
Published: 31 January 2023
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative
Nature Reviews Bioengineering (Nat Rev Bioeng) ISSN 2731-6092 (online)
© 2023 Springer Nature Limited
Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.